In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $1.82.
According to TipRanks, Goldstein is an analyst with an average return of -4.1% and a 31.78% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Incyte, and Nektar Therapeutics.
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.50, which is a 476.92% upside from current levels. In a report released on January 4, Truist Financial also maintained a Buy rating on the stock with a $6.00 price target.
See the top stocks recommended by analysts >>
Based on Autolus Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.37 million and a GAAP net loss of $42.77 million. In comparison, last year the company had a GAAP net loss of $33.99 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- Autolus enters non-exclusive license agreement with Cabaletta
- Autolus Announces Partial Exercise of Underwriters’ Option to Purchase Additional ADSs
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
- Autolus Therapeutics to present clinical data updates at ASH meeting
- Autolus Therapeutics 75M share Spot Secondary priced at $2.00